Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.
Oza AM, Eisenhauer EA, Elit L, Cutz JC, Sakurada A, Tsao MS, Hoskins PJ, Biagi J, Ghatage P, Mazurka J, Provencher D, Dore N, Dancey J, Fyles A. Oza AM, et al. Among authors: cutz jc. J Clin Oncol. 2008 Sep 10;26(26):4319-25. doi: 10.1200/JCO.2007.15.8808. Epub 2008 Jun 30. J Clin Oncol. 2008. PMID: 18591547 Clinical Trial.
Erlotinib in lung cancer - molecular and clinical predictors of outcome.
Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, Marrano P, da Cunha Santos G, Lagarde A, Richardson F, Seymour L, Whitehead M, Ding K, Pater J, Shepherd FA. Tsao MS, et al. Among authors: cutz jc. N Engl J Med. 2005 Jul 14;353(2):133-44. doi: 10.1056/NEJMoa050736. N Engl J Med. 2005. PMID: 16014883 Free article. Clinical Trial.
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.
Zhu CQ, da Cunha Santos G, Ding K, Sakurada A, Cutz JC, Liu N, Zhang T, Marrano P, Whitehead M, Squire JA, Kamel-Reid S, Seymour L, Shepherd FA, Tsao MS; National Cancer Institute of Canada Clinical Trials Group Study BR.21. Zhu CQ, et al. Among authors: cutz jc. J Clin Oncol. 2008 Sep 10;26(26):4268-75. doi: 10.1200/JCO.2007.14.8924. Epub 2008 Jul 14. J Clin Oncol. 2008. PMID: 18626007
Developing ALK Immunohistochemistry and In Situ Hybridization Proficiency Testing for Non-Small Cell Lung Cancer in Canada: Canadian Immunohistochemistry Quality Control Challenges and Successes.
Cheung CC, Garratt J, Won J, Cutz JC, Gilks BC, Tsao M, Torlakovic EE. Cheung CC, et al. Among authors: cutz jc. Appl Immunohistochem Mol Morphol. 2015 Nov-Dec;23(10):677-81. doi: 10.1097/PAI.0000000000000267. Appl Immunohistochem Mol Morphol. 2015. PMID: 26551338 Clinical Trial.
Translation of Knowledge to Practice-Improving Awareness in NSCLC Molecular Testing.
Zer A, Cutz JC, Sekhon H, Hwang DM, Sit C, Maganti M, Sung M, Binnie M, Brade A, Chung TB, Kamel-Reid S, Paul N, Tsao MS, Waddell T, da Cunha Santos G, Patel M, Carter RF, Leighl NB. Zer A, et al. Among authors: cutz jc. J Thorac Oncol. 2018 Jul;13(7):1004-1011. doi: 10.1016/j.jtho.2018.03.005. Epub 2018 Mar 11. J Thorac Oncol. 2018. PMID: 29535011 Free article.
Crizotinib inhibition of ROS1-positive tumours in advanced non-small-cell lung cancer: a Canadian perspective.
Bebb DG, Agulnik J, Albadine R, Banerji S, Bigras G, Butts C, Couture C, Cutz JC, Desmeules P, Ionescu DN, Leighl NB, Melosky B, Morzycki W, Rashid-Kolvear F, Lab C, Sekhon HS, Smith AC, Stockley TL, Torlakovic E, Xu Z, Tsao MS. Bebb DG, et al. Among authors: cutz jc. Curr Oncol. 2019 Aug;26(4):e551-e557. doi: 10.3747/co.26.5137. Epub 2019 Aug 1. Curr Oncol. 2019. PMID: 31548824 Free PMC article.
Canadian Multicenter Project on Standardization of Programmed Death-Ligand 1 Immunohistochemistry 22C3 Laboratory-Developed Tests for Pembrolizumab Therapy in NSCLC.
Torlakovic E, Albadine R, Bigras G, Boag A, Bojarski A, Cabanero M, Camilleri-Broët S, Cheung C, Couture C, Craddock KJ, Cutz JC, Dhamanaskar P, Fiset PO, Hossain M, Hwang DM, Ionescu D, Itani D, Kelly MM, Kwan K, Lim HJ, Nielsen S, Qing G, Sekhon H, Spatz A, Waghray R, Wang H, Xu Z, Tsao MS. Torlakovic E, et al. Among authors: cutz jc. J Thorac Oncol. 2020 Aug;15(8):1328-1337. doi: 10.1016/j.jtho.2020.03.029. Epub 2020 Apr 15. J Thorac Oncol. 2020. PMID: 32304736 Free article.
Canadian anaplastic lymphoma kinase study: a model for multicenter standardization and optimization of ALK testing in lung cancer.
Cutz JC, Craddock KJ, Torlakovic E, Brandao G, Carter RF, Bigras G, Deschenes J, Izevbaye I, Xu Z, Greer W, Yatabe Y, Ionescu D, Karsan A, Jung S, Fraser RS, Blumenkrantz M, Lavoie J, Fortin F, Bojarski A, Côté GB, van den Berghe JA, Rashid-Kolvear F, Trotter M, Sekhon HS, Albadine R, Tran-Thanh D, Gorska I, Knoll JH, Xu J, Blencowe B, Iafrate AJ, Hwang DM, Pintilie M, Gaspo R, Couture C, Tsao MS. Cutz JC, et al. J Thorac Oncol. 2014 Sep;9(9):1255-63. doi: 10.1097/JTO.0000000000000239. J Thorac Oncol. 2014. PMID: 25122422 Free article. Clinical Trial.
64 results